“The SORT OUT IV evidence shows that the two drug-eluting stents work very well,” Rogers said. “The unique design features of the CYPHER continues to make a choice of treatment for interventional cardiologists is essential in today.”The researchers reported the results of the SORT-OUT IV, comparing Cypher, Cordis Corporation (R) Sirolimus-eluting Coronary Stent and Abbott’s XIENCE V everolimus-eluting stent in the primary endpoint of MACE (acute coronary events) to nine months. These results were presented at the annual meeting of the TCT (TCT 2010) held last week in Washington DC. This study adds to the body of unprecedented safety and efficacy data on this with the CYPHER XIENCE V compared to the most recently approved in a contemporary setting.
** The third-party trademarks contained herein are trademarks of their respective owners.
The TRI OUT large randomized study included over 2600 patients in IV a wide range of injuries and complexity of patients. The study was designed to see if the XIENCE V is the non-inferiority of the CYPHER. The two drug-eluting stents performed better than expected for the composite endpoint of MACE (4.9% for XIENCE V stent vs. 5.2% for Cypher), these data confirm non-inferiority of the XIENCE stent Cypher (non-inferiority p = 0 , 01). There was no statistically significant difference markers security keys, including the incidence of cardiac death (1.9% for XIENCE V stent vs. 1.4% for Cypher, p = 0.31), myocardial infarction (1.1% for XIENCE V vs. 1.4% for Cypher, p = 0.48), or definite or probable stent thrombosis (0.9% for XIENCE V stent vs. 0, 9% for Cypher, p = 0.83).
The CYPHER has been chosen by cardiologists worldwide to treat approximately three million patients. The safety and efficacy of the device is supported by a robust clinical trial program with more than 70 studies that examined the performance of the CYPHER stent in a wide range of patients.
“The consortium has used as a comparator Cypher solve a series of studies to date, no new stent Cypher has proven to be an advantage in terms of safety or effectiveness,” said Campbell Rogers, MD, Chief Scientific Officer and Head, Global Research and Development, Cordis Corporation. “The safety and efficacy of the CYPHER randomized in this study reinforce the real world always supported the excellent clinical outcomes seen in the last 10 years.”
Cordis Corporation has entered into an exclusive worldwide license with Wyeth for the localized delivery of sirolimus in certain fields of use, including delivery via vascular stenting. Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune. Rapamune is a trademark of Wyeth Pharmaceuticals.